Windtree Therapeutics Stock Net Income
| WINT Stock | USD 0.02 0.00 0.00% |
As of the 27th of January, Windtree Therapeutics maintains the Standard Deviation of 10.1, market risk adjusted performance of (1.74), and Mean Deviation of 6.65. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Windtree Therapeutics, as well as the relationship between them.
Analyzing historical trends in various income statement and balance sheet accounts from Windtree Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Windtree Therapeutics' valuation are summarized below:Windtree Therapeutics does not presently have any fundamental gauges for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Windtree Therapeutics. If investors know Windtree will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Windtree Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Windtree Therapeutics is measured differently than its book value, which is the value of Windtree that is recorded on the company's balance sheet. Investors also form their own opinion of Windtree Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Windtree Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Windtree Therapeutics' market value can be influenced by many factors that don't directly affect Windtree Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Windtree Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Windtree Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Windtree Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Windtree Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Windtree Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Windtree Therapeutics.
| 10/29/2025 |
| 01/27/2026 |
If you would invest 0.00 in Windtree Therapeutics on October 29, 2025 and sell it all today you would earn a total of 0.00 from holding Windtree Therapeutics or generate 0.0% return on investment in Windtree Therapeutics over 90 days. Windtree Therapeutics is related to or competes with Revelation Biosciences, Dermata Therapeutics, Avenue Therapeutics, XORTX Therapeutics, Virax Biolabs, Ainos, and NewcelX. Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for ... More
Windtree Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Windtree Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Windtree Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 58.33 | |||
| Value At Risk | (20.00) | |||
| Potential Upside | 16.67 |
Windtree Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Windtree Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Windtree Therapeutics' standard deviation. In reality, there are many statistical measures that can use Windtree Therapeutics historical prices to predict the future Windtree Therapeutics' volatility.| Risk Adjusted Performance | (0.14) | |||
| Jensen Alpha | (2.16) | |||
| Total Risk Alpha | (3.03) | |||
| Treynor Ratio | (1.75) |
Windtree Therapeutics January 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.14) | |||
| Market Risk Adjusted Performance | (1.74) | |||
| Mean Deviation | 6.65 | |||
| Coefficient Of Variation | (488.20) | |||
| Standard Deviation | 10.1 | |||
| Variance | 102.08 | |||
| Information Ratio | (0.21) | |||
| Jensen Alpha | (2.16) | |||
| Total Risk Alpha | (3.03) | |||
| Treynor Ratio | (1.75) | |||
| Maximum Drawdown | 58.33 | |||
| Value At Risk | (20.00) | |||
| Potential Upside | 16.67 | |||
| Skewness | (0.28) | |||
| Kurtosis | 1.94 |
Windtree Therapeutics Backtested Returns
Windtree Therapeutics shows Sharpe Ratio of -0.2, which attests that the company had a -0.2 % return per unit of risk over the last 3 months. Windtree Therapeutics exposes nineteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Windtree Therapeutics' Mean Deviation of 6.65, standard deviation of 10.1, and Market Risk Adjusted Performance of (1.74) to validate the risk estimate we provide. The firm maintains a market beta of 1.19, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Windtree Therapeutics will likely underperform. At this point, Windtree Therapeutics has a negative expected return of -2.07%. Please make sure to check out Windtree Therapeutics' jensen alpha and rate of daily change , to decide if Windtree Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.80 |
Very good predictability
Windtree Therapeutics has very good predictability. Overlapping area represents the amount of predictability between Windtree Therapeutics time series from 29th of October 2025 to 13th of December 2025 and 13th of December 2025 to 27th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Windtree Therapeutics price movement. The serial correlation of 0.8 indicates that around 80.0% of current Windtree Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.8 | |
| Spearman Rank Test | 0.47 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Windtree Therapeutics reported net income of (1.79 Million). This is 100.52% lower than that of the Biotechnology sector and 102.55% lower than that of the Health Care industry. The net income for all United States stocks is 100.31% higher than that of the company.
Windtree Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Windtree Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Windtree Therapeutics could also be used in its relative valuation, which is a method of valuing Windtree Therapeutics by comparing valuation metrics of similar companies.Windtree Therapeutics is currently under evaluation in net income category among its peers.
Windtree Fundamentals
| Return On Equity | -4.13 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 13.39 M | ||||
| Shares Outstanding | 33.63 M | ||||
| Shares Owned By Institutions | 0.07 % | ||||
| Number Of Shares Shorted | 1.79 M | ||||
| Price To Earning | (0.05) X | ||||
| Price To Book | 0.61 X | ||||
| Price To Sales | 660.53 X | ||||
| Gross Profit | (17.79 M) | ||||
| EBITDA | (1.47 M) | ||||
| Net Income | (1.79 M) | ||||
| Cash And Equivalents | 11.38 M | ||||
| Cash Per Share | 0.37 X | ||||
| Total Debt | 1.82 M | ||||
| Debt To Equity | 0.95 % | ||||
| Current Ratio | 2.47 X | ||||
| Book Value Per Share | 0.39 X | ||||
| Cash Flow From Operations | (15.4 M) | ||||
| Short Ratio | 0.08 X | ||||
| Earnings Per Share | 62.60 X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 14 | ||||
| Beta | 0.55 | ||||
| Market Capitalization | 2.02 M | ||||
| Total Asset | 27.88 M | ||||
| Retained Earnings | (846.61 M) | ||||
| Working Capital | (3.14 M) | ||||
| Current Asset | 40.79 M | ||||
| Current Liabilities | 11.07 M | ||||
| Net Asset | 27.88 M |
About Windtree Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Windtree Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Windtree Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Windtree Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.